These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35596184)

  • 1. Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes.
    Song L; Zhao X; Chen R; Li J; Zhou J; Liu C; Zhou P; Wang Y; Chen Y; Zhao H; Yan H
    Cardiovasc Diabetol; 2022 May; 21(1):80. PubMed ID: 35596184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.
    Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
    Cardiovasc Diabetol; 2020 Oct; 19(1):167. PubMed ID: 33023603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI).
    Wang J; Han P; Gao M; Xiao J; Li X; Zhang N; Ma J; Cui Z; Yao T; Chen Y; Gao J; Liu Y
    Hellenic J Cardiol; 2022; 63():22-31. PubMed ID: 34058371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
    Navarese EP; Kolodziejczak M; Winter MP; Alimohammadi A; Lang IM; Buffon A; Lip GY; Siller-Matula JM
    Int J Cardiol; 2017 Jan; 227():644-649. PubMed ID: 27810295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Circulating PCSK9 With Ischemia-Reperfusion Injury in Acute ST-Elevation Myocardial Infarction.
    Tiller C; Holzknecht M; Lechner I; Oberhollenzer F; von der Emde S; Kremser T; Gollmann-Tepeköylü C; Mayr A; Bauer A; Metzler B; Reinstadler SJ; Reindl M
    Circ Cardiovasc Imaging; 2024 Aug; 17(8):e016482. PubMed ID: 39163371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI.
    Zhao X; Song L; Wang Y; Li J; Zhou J; Chen R; Liu C; Zhou P; Sheng Z; Chen Y; Zhao H; Yan H
    J Inflamm Res; 2021; 14():5319-5335. PubMed ID: 34703271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Jiang Z; Zhang R; Sun M; Liu Q; Wang S; Wang W; Zhao Q; Zhang H; Wang Y; Hou J; Yu B
    Can J Cardiol; 2018 Dec; 34(12):1606-1612. PubMed ID: 30527148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of C-reactive protein-albumin-lymphocyte (CALLY) index after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    Ji H; Luo Z; Ye L; He Y; Hao M; Yang Y; Tao X; Tong G; Zhou L
    Int Immunopharmacol; 2024 Nov; 141():112860. PubMed ID: 39142002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of D-dimer to lymphocyte ratio in predicting clinical outcomes after percutaneous coronary intervention in ST-segment elevation myocardial infarction patients: A retrospective study.
    Cao S; Liu Y; Ye J; Wang Y; Wang Z; Li C; Jin T; Wu J; Zong G
    Int Immunopharmacol; 2024 Feb; 128():111556. PubMed ID: 38241843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study.
    Zhao X; Song L; Li J; Zhou J; Li N; Yan S; Chen R; Wang Y; Liu C; Zhou P; Sheng Z; Chen Y; Zhao H; Yan H
    J Inflamm Res; 2023; 16():269-282. PubMed ID: 36713050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative lymphocyte to C-reactive protein ratio: A new prognostic indicator of post-primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    Liu Y; Ye T; Chen L; Xu B; Wu G; Zong G
    Int Immunopharmacol; 2023 Jan; 114():109594. PubMed ID: 36525793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive association between stress hyperglycemia ratio and pulmonary infection in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Lin Z; Liang X; Zhang Y; Dai Y; Zeng L; Chen W; Kong S; He P; Duan C; Liu Y
    Cardiovasc Diabetol; 2023 Mar; 22(1):76. PubMed ID: 37004002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.
    Cao YX; Jin JL; Sun D; Liu HH; Guo YL; Wu NQ; Xu RX; Zhu CG; Dong Q; Sun J; Li JJ
    J Transl Med; 2019 Nov; 17(1):367. PubMed ID: 31711505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum circRNA (Circ)_0051386 assists in the diagnosis of acute ST-segment elevation myocardial infarction and prediction of the occurrence of major adverse cardiovascular events after percutaneous coronary intervention.
    Xu J; Wang Z; Ai Y; Wen Y
    Acta Cardiol; 2024 Apr; 79(2):215-223. PubMed ID: 38456718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
    Choi IJ; Lim S; Lee D; Lee WJ; Lee KY; Kim MJ; Jeon DS
    Am J Cardiol; 2020 Oct; 133():54-60. PubMed ID: 32798044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of
    Santoso A; Yulianto Y; Simarmata H; Putra AN; Listiyaningsih E
    Int J Angiol; 2021 Mar; 30(1):22-28. PubMed ID: 34025093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of eosinophil percentage and high-sensitivity C-reactive protein predicts in-hospital major adverse cardiac events in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
    Ye L; Bai HM; Jiang D; He B; Wen XS; Ge P; Zhang DY
    J Clin Lab Anal; 2020 Sep; 34(9):e23367. PubMed ID: 32441412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between White Blood Count to Mean Platelet Volume Ratio and Clinical Outcomes and Severity of Coronary Artery Disease in Patients Undergoing Primary Percutaneous Coronary Intervention.
    Emre AR; Yasar KA; Atakan Y; Orhan C; Murathan K
    Cardiovasc Ther; 2020; 2020():9625181. PubMed ID: 32934665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial.
    Fabris E; Van't Hof A; Hamm CW; Lapostolle F; Lassen JF; Goodman SG; Ten Berg JM; Bolognese L; Cequier A; Chettibi M; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Cantor WJ; Kerneis M; Diallo A; Vicaut E; Montalescot G;
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):E369-E377. PubMed ID: 30302940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.